Literature DB >> 24396439

Cryptogenic organizing pneumonia associated with radiation: A report of two cases.

Sachika Nogi1, Hidetsugu Nakayama1, Yu Tajima1, Mitsuru Okubo1, Ryuji Mikami1, Shinji Sugahara1, Soichi Akata1, Koichi Tokuuye1.   

Abstract

Cryptogenic organizing pneumonia (COP) following radiotherapy is occasionally diagnosed as radiation pneumonitis or bacterial pneumonia. The current study presents two cases of COP following radiotherapy: A 48-year-old premenopausal female with breast cancer and an 84-year-old male with non-small cell lung cancer. In the cases of breast cancer and lung cancer, patients were first diagnosed with bacterial pneumonia and radiation pneumonitis, respectively. In the two cases, computed tomography disclosed the migration of ground glass shadows, which were finally resolved without any fibrotic changes. The two cases were finally diagnosed as COP associated with radiotherapy. When an infiltrating shadow is present outside of the irradiated field, COP must be included in the differential diagnosis.

Entities:  

Keywords:  breast cancer; cryptogenic organizing pneumonia; irradiation; non-small cell lung cancer

Year:  2013        PMID: 24396439      PMCID: PMC3881924          DOI: 10.3892/ol.2013.1716

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

Lange initially described obliterative bronchiolitis in 1901 (1) and the unique clinical and histological characteristics of this pulmonary disease are well-known. Epler et al coined the term ‘bronchiolitis obliterans organizing pneumonia’ (BOOP) to describe this condition. In 1985, the authors described 50 patients with BOOP and showed that it was a clinicopathological entity that was distinct from irreversible pulmonary fibrosis (2). Histologically, BOOP is characterized by granulation tissue and polypoid masses in the lumens of the small airways, alveolar ducts and certain alveoli. Radiographs show an unusual pattern of patchy densities with a ‘ground glass’ appearance. In 2001, the American Thoracic Society and the European Respiratory Society standardized the classification of idiopathic interstitial pneumonia with the presence of BOOP as cryptogenic organizing pneumonia (COP) (3). Idiopathic interstitial pneumonia may be associated with post-respiratory infection, drug addiction, connective tissue disease, organ transplantation, inhalation of fumes and radiotherapy (4,5). Crestani et al defined COP associated with radiotherapy for breast cancer as the presence of the following conditions: i) radiation therapy to the breast within 12 months of symptom onset; ii) general and/or respiratory symptoms lasting for ≥2 weeks; iii) infiltrations outside the irradiated volume; and iv) no other specific cause of the symptoms (6). Although there are a number of previous studies that have reported COP following radiotherapy for breast cancer, reports of COP following radiotherapy for non-small cell lung cancer (NSCLC) are rare. COP associated with radiotherapy is occasionally diagnosed as radiation pneumonitis or bacterial pneumonia. The current study presents two cases of COP following radiotherapy, one breast cancer patient and the other a patient with NSCLC. Written informed consent was obtained from the patients.

Case reports

Breast cancer case

A 48-year-old premenopausal female with cancer in the left breast underwent breast conservative surgery and sentinel lymph node biopsy. The pathological examination led to a diagnosis of stage I (pT1cN0M0) invasive ductal carcinoma that was estrogen receptor-positive and Her2 receptor-positive. The patient underwent a second surgery following observations of a positive surgical margin, and, three months following the initial surgery, underwent radiotherapy of 50 Gy in 25 fractions to the left whole breast using a 4-MV X-ray and a tangential field technique. An additional dose of 10 Gy in five fractions to the tumor bed was used as a boost therapy with 9 MeV electrons (Fig. 1A). The patient was treated with anti-estrogen therapy consisting of oral tamoxifen plus subcutaneous luteinizing hormone-releasing hormone agonist.
Figure 1

Dosimetry of (A) a 46-year-old female with breast cancer and (B) an 84-year-old male with non-small cell lung cancer.

The patient experienced a fever (38.8°C) and developed a productive cough four months following the completion of radiotherapy. The patient’s laboratory results are shown in Table I. A chest X-ray showed an infiltrating shadow in the upper lobe of the left lung. Computed tomography (CT) showed consolidation with air bronchogram in the left upper lobe and ground glass densities in the left lower and right upper lobes (Fig. 2A and 2B). As these shadows appeared outside of the irradiated volume, the patient was diagnosed with bacterial pneumonia, despite no pathological confirmation. The patient was treated with oral levofloxacin (500 mg for 14 days). Four weeks following the completion of levofloxacin therapy, a CT scan showed that the original consolidation and ground glass densities had resolved, but new ground glass densities had appeared in the right upper lobe. Transbronchial lung biopsy revealed alveolar septal and focal intra-alveolar fibrosis; these observations were consistent with an observation of organizing bronchopneumonia. Examination of bronchoalveolar lavage (BAL) fluid showed the following: 34% lymphocytes, 5% neutrophils, 19% eosinophils and 42% macrophages. The CD4/CD8 ratio was 0.78. Based on these results, the patient was diagnosed with COP. After 8 months, all symptoms were spontaneously resolved (Fig. 2C and 2D). A CT showed only slight fibrosis in the lung that was consistent with the irradiated volume. The patient began taking herbal medicine containing Scutellaria root to treat menopause symptoms. However, two weeks following this, the patient experienced symptoms similar to those experienced with COP. The CT scan showed new ground glass densities in the right upper lobe and the patient was suspected to have a recurrence of COP. The patient stopped taking the herbal medicine, and symptoms and shadows on the CT resolved.
Table I

Patient laboratory results.

ParametersBreast cancer patientLung cancer patient
Hematology
 WBC count, cells/μl9.9×1036.2×103
  Neutrophils, %86.774.4
  Lymphocytes, %6.815.2
  Eosinophils, %2.42.4
RBC, cells/μl4.55×1064.24×106
Hb, g/dl12.813.7
Ht, %38.541.1
Plt, cells/μl3.79×1052.11×105
Serology
 CRP, mg/dl9.511.8
 KL-6, U/ml310833
Biochemistry
 TP, g/dl7.37.0
 T-Bil, mg/dl0.350.97
 GOT, IU/l3020
 GPT, IU/l3924
 LDH, IU/l215168
 ALP, IU/l750274
 γ-GTP, IU/l17754
 BUN, mg/dl8.519.6
 Cr, mg/dl0.540.66
 Na, mEq/l143141
 K, mEq/l4.04.3
 Cl, mEq/l106104
BAL fluid
 Total cell count, cells/ml2.5×107-
 Macrophages, %42.4-
 Lymphocytes, %34.0-
 Neutrophils, %4.8-
 Eosinophils, %18.8-
 CD4/CD80.78-

WBC, white blood cell; BAL, bronchoalveolar lavage.

Figure 2

Chest computed tomography of the breast cancer patient following completion of radiotherapy showed (A and B) consolidation with air bronchograms in the left upper lobe and the superior segment of the left lower lobe at 4 months and (C and D) complete resolution in the left upper and left lower lobes at 13 months.

NSCLC case

An 84-year-old male exhibited clinical stage IIA (cT1bN1M0) squamous cell lung cancer in the right upper lobe and was considered unsuitable for surgery due to poor pulmonary function. The patient underwent radiotherapy to the primary tumor and metastatic lymph node, consisting of 60 Gy in 30 fractions using 10-MV X-rays (Fig. 1B). The patient was referred to Tokyo Medical University (Tokyo, Japan) due to a non-productive cough four months following the completion of radiotherapy. The patient was afebrile, but blood CRP levels were elevated (11.8 mg/dl). The patient’s laboratory results are shown in Table I. The chest radiograph showed a patchy shadow in the right middle lobe. CT disclosed consolidation in the right lower lobe that was consistent with the irradiation volume (Fig. 3A). The patient was diagnosed with radiation pneumonitis and prescribed oral prednisone at a dose of 30 mg per day. After two weeks, the patient’s symptoms and laboratory results improved, and the patchy shadow on the chest radiograph disappeared. The prednisone dose was tapered and discontinued after two months. The patient again developed a non-productive cough without fever three months following the first presentation with a cough. CT showed an extended consolidated shadow outside the irradiated volume (Fig. 3B) that was resolved following the administration of oral prednisone. The prednisone was discontinued and 11 months following the completion of radiotherapy, a follow-up CT showed an infiltrated shadow in the lower lobes (Fig. 3C). The white blood cell count was 4.8×103 cells/μl and the C-reactive protein levels were 1.1 mg/dl. The patient was diagnosed with COP due to their responsiveness to prednisone, migration of the consolidation on CT and resolution of fibrosis following shadow consolidation. The patient again received daily oral prednisone (20 mg/day) for four months, which was tapered over seven months. The infiltrated shadows disappeared following 18 months of radiotherapy (Fig. 3D).
Figure 3

Chest computed tomography of the lung cancer patient following the completion of radiotherapy showed (A) consolidation with ground grass shadow in the irradiated field in the right lower lobe and right pleural effusion at 4 months, (B) consolidation of the extended irradiated volume and increased pleural effusion at 7 months, (C) constriction of the ground grass shadow and a migrated shadow in the lower two lobes at 11 months and (D) resolution in the lower lobe (i.e. no fibrosis) at 18 months.

Discussion

The two cases presented in the current study exhibited CTs that showed consolidations with a ground glass appearance. In the two cases, the shadows migrated and were finally resolved without any fibrotic changes in the CT examination. No observations of bacterial or viral infection were identified. These observations were compatible with COP according to the criteria of Crestani et al(6), who defined COP to be associated with radiotherapy. Takigawa et al reported that four out of 157 (2.5%) patients who underwent radiotherapy following breast conservative surgery developed COP (7). The use of tamoxifen, chemotherapy and breast position were factors that were not associated with developing COP. However, the eosinophil and neutrophil counts were increased in the BAL fluid and the CD4/CD8 ratio was >2.0. In the two present cases, the eosinophil count was elevated but the CD4/CD8 ratio was <1.0. Toma et al previously reported that there were increased mast cells in the BAL fluid of five patients who had developed COP following radiotherapy (8). In addition, Roberts et al reported that the CD4/CD8 ratio in the BAL fluid was elevated in one patient with COP following radiotherapy (9), while Nagai et al found that a decreased CD4/CD8 ratio was consistent with idiopathic COP (10). Overall, these disparate observations suggested that the CD4/CD8 ratio in the BAL fluid of patients with COP associated with radiotherapy is uncertain, as detailed subset examinations of lymphocytes in BAL fluid have not been previously conducted. Previously, Ogo et al conducted a multi-institutional survey that found that 37 out of 2,056 (1.8%) patients with breast cancer exhibited COP (11). However, the authors did not identify any correlation between patient characteristics and the occurrence of COP. Kubo et al reported that 12 out of 413 (2.9%) patients exhibited COP (12). The central lung distance (>1.8 cm) was the only significant risk factor; notably, nodal status, location, field size, use of chemotherapy and ipsilateral V20 were not risk factors. Katayama et al reported that 16 out of 702 (2.3%) patients developed COP following breast conservative surgery (13). In that study, multivariate and univariate analyses showed that an age of >50 years and endocrine therapy were risk factors for COP. The authors noted that radiation-induced COP occurred >4 months following radiotherapy, consistent with the cases of the present study. These results suggested that the COP occurred in 2–3% of patients with tangential breast irradiation. Murai et al previously reported that nine out of 189 patients developed COP following stereotactic radiotherapy of the lung (14) and calculated the COP incidence at 1 and 2 years to be 4.0 and 5.2%, respectively. No association was found between COP and radiation dose, but prior radiation pneumonitis was a marked risk factor for COP. The authors suggested that following stereotactic radiotherapy, patients must be carefully followed for ≥2 years, particularly those with symptoms consistent with radiation pneumonitis. To the best of our knowledge, COP following conventional irradiation of the lung has not been reported previously. In the current case, a consolidation shadow was identified in the right lower lobes below the irradiated volume. Previously, Oie et al observed that COP appeared near the area affected by radiation pneumonitis (15). Numerous studies have previoulsy reported that a marked improvement may be achieved by the administration of corticosteroids, but relapses often occur when the dose is tapered. Katayama et al reported that two out of 16 patients required corticosteroids for >3 years (13), while Narabayashi et al described radiation-induced COP that was refractory to corticosteroids (16). Stover et al suggested that macrolides may be useful in these cases (17). By contrast, Ogo et al reported that clinical and radiology observations improved in 50% of patients without corticosteroid treatment (11), as was demonstrated in the current breast cancer case. In conclusion, when an infiltrating shadow is present outside of the irradiated field, COP must be included in the differential diagnosis.
  16 in total

1.  Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: radiation-induced lung toxicity.

Authors:  N Takigawa; Y Segawa; T Saeki; M Kataoka; M Ida; D Kishino; K Fujiwara; S Ohsumi; K Eguchi; S Takashima
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-10-01       Impact factor: 7.038

Review 2.  Bronchiolitis obliterans organizing pneumonia, 25 years: a variety of causes, but what are the treatment options?

Authors:  Gary R Epler
Journal:  Expert Rev Respir Med       Date:  2011-06       Impact factor: 3.772

3.  A newly recognized syndrome--radiation-related bronchiolitis obliterans and organizing pneumonia. A case report and literature review.

Authors:  D E Stover; F Milite; M Zakowski
Journal:  Respiration       Date:  2001       Impact factor: 3.580

4.  The bronchoalveolar lavage pattern in radiation pneumonitis secondary to radiotherapy for breast cancer.

Authors:  Claudia Lucia Toma; Aneta Serbescu; Mihai Alexe; Luminita Cervis; Diana Ionita; Miron Alexandru Bogdan
Journal:  Maedica (Buchar)       Date:  2010-12

5.  Risk factors for radiation pneumonitis caused by whole breast irradiation following breast-conserving surgery.

Authors:  Akiko Kubo; Kyosuke Osaki; Takashi Kawanaka; Shunsuke Furutani; Hitoshi Ikushima; Hiromu Nishitani
Journal:  J Med Invest       Date:  2009-08

6.  Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction.

Authors:  C M Roberts; E Foulcher; J J Zaunders; D H Bryant; J Freund; D Cairns; R Penny; G W Morgan; S N Breit
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

7.  A survey of radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy in Japan.

Authors:  Etsuyo Ogo; Ritsuko Komaki; Kiminori Fujimoto; Masafumi Uchida; Toshi Abe; Katsumasa Nakamura; Michihide Mitsumori; Kenji Sekiguchi; Yuko Kaneyasu; Naofumi Hayabuchi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-03       Impact factor: 7.038

Review 8.  Bronchoalveolar lavage in idiopathic interstitial lung diseases.

Authors:  Sonoko Nagai; Tomohiro Handa; Yutaka Ito; Minoru Takeuchi; Takateru Izumi
Journal:  Semin Respir Crit Care Med       Date:  2007-10       Impact factor: 3.119

9.  Analysis of factors associated with radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy.

Authors:  Norihisa Katayama; Shuhei Sato; Kuniaki Katsui; Mitsuhiro Takemoto; Toshihide Tsuda; Atsushi Yoshida; Tsuneharu Morito; Tomio Nakagawa; Akifumi Mizuta; Takahiro Waki; Harutaka Niiya; Susumu Kanazawa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-26       Impact factor: 7.038

10.  Radiation-induced lung injury: a hypersensitivity pneumonitis?

Authors:  P G Gibson; D H Bryant; G W Morgan; M Yeates; V Fernandez; R Penny; S N Breit
Journal:  Ann Intern Med       Date:  1988-08-15       Impact factor: 25.391

View more
  5 in total

Review 1.  Systematic review of postradiotherapy bronchiolitis obliterans organizing pneumonia in women with breast cancer.

Authors:  Gary R Epler; Eileen M Kelly
Journal:  Oncologist       Date:  2014-10-31

Review 2.  Radiation-Induced Organizing Pneumonia: A Characteristic Disease that Requires Symptom-Oriented Management.

Authors:  Keisuke Otani; Yuji Seo; Kazuhiko Ogawa
Journal:  Int J Mol Sci       Date:  2017-01-27       Impact factor: 5.923

3.  Post-radiotherapy maintenance treatment with fluticasone propionate and salmeterol for lung cancer patients with grade III radiation pneumonitis: A case report.

Authors:  Pingping Zhang; Hongxia Yan; Sheng Wang; Jindan Kai; Guoliang Pi; Yi Peng; Xiyou Liu; Junwei Sun
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

4.  Urgent lung transplantation for thymic neoplasm-associated severe constrictive bronchiolitis with bronchiectasis and radiotherapy-induced organizing pneumonia: A case report.

Authors:  Tomaž Štupnik; Marija Iča Dolenšek; Jernej Mlakar; Karmen Stanič; Matevž Harlander; Sabina Škrgat
Journal:  Thorac Cancer       Date:  2021-04-08       Impact factor: 3.500

5.  Spontaneous resolution of thoracic radiation therapy-induced organizing pneumonia: A case series.

Authors:  Hidenori Kawakami; Takao Miyabayashi; Chikako Tsubata; Kyuma Ota; Takashi Ishida; Osamu Kobayashi
Journal:  Respir Med Case Rep       Date:  2019-01-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.